The exploratory study analyzed saliva from 66 patients with relapsing-remitting multiple sclerosis (RRMS) before therapy and 31 healthy controls.
2
Of 623 proteins assessed statistically, 116 differed between patients with RRMS before treatment and healthy controls, compared with 54 after 6 months of therapy.
3
After 6 months, 38 proteins shifted toward control levels, 25 differed from controls only at follow-up, and 28 remained altered at both patient time points.
4
Altered proteins were linked to innate immunity, neutrophil degranulation, cytokine signaling, programmed cell death, and protein folding.
5
The 50-protein panel distinguished study groups within this cohort but is not ready for clinical use; larger multicenter studies are needed.